Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$39.18

0.84 (2.19%)

, BMY

Bristol-Myers

$46.88

1.76 (3.90%)

19:39
01/06/19
01/06
19:39
01/06/19
19:39

Fly Intel: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. In a tweet, President Donald Trump said that, "Drug makers and companies are not living up to their commitments on pricing. Not being fair to the consumer, or to our Country!" Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). 2. Apple (AAPL) and Samsung (SSNLF) announced a deal, under which the iPhone maker will begin offering iTunes movies and TV shows on Samsung TV sets, according to Bloomberg. 3. Last summer when Apple shares soared, analysts kept raising their price targets to higher and higher levels, but this week after the company dropped a guidance bombshell, many of the same analysts slashed their forecasts, Tae Kim wrote in this week's edition of Barron's. In the end, investors are better off holding on anyway, he contended. While Apple's stock performance is currently tied to iPhone sales, its future is tied to a lucrative installed base that's estimated to be 1.3B devices, and CEO Tim Cook needs to find a better way to monetize that base with more services revenue, the publication added. 4. AT&T (T) subsidiary Warner Bros' "Aquaman" stayed atop the chart in its third weekend with $30.7M for a North American total of $259.7M and a global tally of $940.7M. Directed by James Wan, "Aquaman" stars Jason Momoa in the titular role alongside Amber Heard, Willem Dafoe, Patrick Wilson and Dolph Lundgren. The film earned an A- CinemaScore and sports a 64% Rotten Tomatoes score. 5. Air Lease (AL), AT&T, DXC Technology (DXC), Morgan Stanley (MS), Mylan (MYL), and Navistar (NAV) saw positive mentions in Barron's.

AZN

AstraZeneca

$39.18

0.84 (2.19%)

BMY

Bristol-Myers

$46.88

1.76 (3.90%)

LLY

Eli Lilly

$114.65

3.36 (3.02%)

GSK

GlaxoSmithKline

$38.62

0.76 (2.01%)

JNJ

Johnson & Johnson

$127.80

1.99 (1.58%)

MRK

Merck

$76.26

2.22 (3.00%)

NVS

Novartis

$85.88

1.1 (1.30%)

PFE

Pfizer

$42.99

0.95 (2.26%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$42.87

0.41 (0.97%)

AAPL

Apple

$148.27

6.18 (4.35%)

SSNLF

Samsung

$0.00

(0.00%)

T

AT&T

$30.33

0.77 (2.60%)

AL

Air Lease

$31.96

2.29 (7.72%)

DXC

DXC Technology

$57.33

2.69 (4.92%)

MS

Morgan Stanley

$41.30

1.62 (4.08%)

MYL

Mylan

$28.85

1.61 (5.91%)

NAV

Navistar

$27.15

0.955 (3.65%)

  • 06

    Jan

  • 06

    Jan

  • 06

    Jan

  • 07

    Jan

  • 07

    Jan

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 09

    Jan

  • 11

    Jan

  • 14

    Jan

  • 17

    Jan

  • 22

    Jan

  • 24

    Jan

  • 27

    Jan

  • 28

    Jan

  • 28

    Jan

  • 29

    Jan

  • 30

    Jan

  • 01

    Feb

  • 16

    Feb

  • 18

    Feb

  • 21

    Feb

  • 25

    Feb

  • 11

    Mar

  • 18

    Mar

  • 20

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

AZN AstraZeneca
$39.18

0.84 (2.19%)

12/13/18
RHCO
12/13/18
INITIATION
Target $48
RHCO
Buy
AstraZeneca initiated with a Buy at SunTrust
SunTrust analyst John Boris started AstraZeneca with a Buy rating and $48 price target.
12/13/18
RHCO
12/13/18
INITIATION
RHCO
SunTrust sees oncology fueling growth for AstraZeneca through 2022
SunTrust analyst John Boris initiated AstraZeneca with a Buy rating and $48 price target, saying oncology should fuel growth through 2022 -- supported by label expansion of its in-line products and new launches -- as well as growth accelerated by 2019 pipeline catalysts.
12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
BMY Bristol-Myers
$46.88

1.76 (3.90%)

01/04/19
EDJN
01/04/19
DOWNGRADE
EDJN
Hold
Bristol-Myers downgraded to Hold from Buy at Edward Jones
01/04/19
BARD
01/04/19
UPGRADE
Target $92
BARD
Outperform
Baird upgrades Celgene to Outperform, says deal discount looks high
As reported previously, Baird analyst Brian Skorney upgraded Celgene (CELG) to Outperform from Neutral. The analyst believes the current price discount to the Bristol-Myers (BMY) deal price does not makes sense based on the probability of the deal closing in the high $90's. He attributes a 35-40% probability of the deal falling through, but he is more bullish on the deal as management is now shown to be willing sellers. Skorney has a $92 price target on Celgene shares, which are up about 2% in pre-market trading to $82 per share.
01/04/19
WELS
01/04/19
NO CHANGE
Target $84
WELS
Market Perform
Celgene price target cut to $84 from $90 at Wells Fargo
Wells Fargo analyst Jim Birchenough maintained a Market Perform rating on Celgene (CELG) but cut his price target to $84 following yesterday's proposed acquisition by Bristol-Myers (BMY). In a research note to investors, Birchenough says he continues to see fundamental risk to both Celgene value and deal closing with poor visibility on long-term growth for the combined company and risk to ongoing Revlimid patent litigation. With the debate on Revlimid generic timing and impact likely to remain on overhang, the analyst believes that the proposed acquisition gives greater leverage to generics, reduces the likelihood of a reasonable settlement and complicates any settlement process.
01/04/19
01/04/19
DOWNGRADE

Outperform
BeiGene downgraded to Outperform at CLSA as Celgene goes 'from friend to foe'
As previously reported, CLSA analyst David Li downgraded BeiGene to Outperform from Buy following the news yesterday of Bristol-Myers' (BMY) proposed acquisition of Celgene (CELG) in a note titled "From friend to foe." He thinks Celgene is unlikely to continue to cooperate with BeiGene on its PD-1 after the deal goes through and also worries about the three commercialized products licensed from Celgene and about the company selling out of its BeiGene stake, he tells investors. He lowered his price target on BeiGene shares to HK$89.86 from HK$121.34.
LLY Eli Lilly
$114.65

3.36 (3.02%)

12/31/18
CANT
12/31/18
NO CHANGE
Target $53
CANT
Overweight
Doctors impressed by tanezumab data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says that investors she's spoken with are expecting the data for Pfizer (PFE) and Eli Lilly's (LLY) tanezumab in the first half of 2019 to be similar to or worse than what was seen in the first Phase 3 data set reported on October 23. However, physicians are impressed by the data and do not believe the rapidly progressive osteoarthritis imbalance would impact their desire to prescribe tanezumab if it is approved, Chen tells investors in a research note. The analyst believes the safety for tanezumab will be better than expected and that the drug could replace opioids for the treatment of pain. If that is right, peak sales potential of tanezumab could be billions of dollars, and drive upside to modest expectations for the drug, says the analyst. She keeps an Overweight rating on Pfizer with a $53 price target.
12/27/18
ARGS
12/27/18
NO CHANGE
Target $135
ARGS
Buy
Argus sees volume growth, expanded indications as 2019 catalysts for Eli Lilly
Argus analyst David Toung kept his Buy rating and $135 price target on Eli Lilly, saying its 2019 catalysts for upside include anticipated volume growth and expanded indications for existing drugs, along with "potential regulatory approvals". The analyst notes that while the company's mature products are seeing slower sales and face patent expiration and the loss of exclusivity, he also expects Eli Lilly to generate earnings growth from margin expansion. Toung is also confident in 2019 contribution of Eli Lilly's recently launched Olumiant for rheumatoid arthritis, Verzenio for the second-line treatment of breast cancer, and Taltz for active psoriatic arthritis.
12/20/18
LEHM
12/20/18
NO CHANGE
Target $120
LEHM
Overweight
Eli Lilly update 'bolsters bullish outlook,' says Barclays
Barclays analyst Geoff Meacham believes Eli Lilly's update yesterday bolstered its bullish outlook. The company's new product growth underscores an attractive investment case, Meacham tells investors in a research note. While the initial 2019 guidance was "solidly ahead of expectations," what is more impressive is the underlying quality, with new products set to drive 45% of 2019's growth outlook, says the analyst. He keeps an Overweight rating on Eli Lilly with a $120 price target.
12/24/18
BMOC
12/24/18
NO CHANGE
Target $132
BMOC
Outperform
Eli Lilly price target raised to $132 from $124 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Eli Lilly to $132 from $124 and kept his Outperform rating, saying that unlike its peers, the company offers "multiple growth drivers and several pipeline assets that could provide meaningful upside." The analyst anticipates Eli Lilly's annualized revenue and earnings growth of 5% and 16% with "significant upside potential" coming from Tanezumab and Alzheimer's program. Araeil further believes that the company's growth, strong R&D and commercial execution prospects "support its premium valuation."
GSK GlaxoSmithKline
$38.62

0.76 (2.01%)

12/27/18
ARGS
12/27/18
NO CHANGE
Target $47
ARGS
Buy
GlaxoSmithKline's high dividend yield 'attractive', says Argus
Argus analyst John Eade kept his Buy rating and $47 price target on GlaxoSmithKline (GSK) with a positive view on its planned joint venture with Pfizer (PFE) combining the companies' consumer businesses. The analyst expects the transaction to boost GlaxoSmithKline shares in the next 2-3 years. Eade also cites the company's 5.2% dividend yield, which he sees as "attractive in a low-interest-rate environment."
12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
JNJ Johnson & Johnson
$127.80

1.99 (1.58%)

01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Outperform
No change in talc litigation risk for Johnson & Johnson, says Wells Fargo
Wells Fargo analyst Larry Biegelsen notes that the NY Times reported that Johnson & Johnson has lost its bid to overturn the $4.7B in a talc trial in St. Louis in July 2018. After checking with the company, the analyst is "able to confirm" that the decision relates to the trial judge denying Johnson & Johnson's post trial motion to set aside the $4.7B verdict. Biegelsen understands that the company had to file this motion in order to file its actual appeal of the decision with the appellate court. As such, he believes the judge's decision should not materially affect the overall talc situation for Johnson & Johnson. Wells Fargo has an Outperform rating on the shares.
01/04/19
CANT
01/04/19
NO CHANGE
Target $100
CANT
Overweight
Cantor Fitzgerald analysis suggests others could bid for Celgene
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Celgene (CELG) with a $100 price target after the company reached an agreement to be acquired by Bristol-Myers Squibb (BMY). Bristol "likely got a good deal, although Celgene has intellectual property and pipeline uncertainties that are key moving pieces," Young tells investors in a research note. Her estimated net present value for Celgene is $80B, assuming some cost synergies, versus the $74B equity valuation in the Bristol deal, excluding the contingent value rights. Young's analysis indicates that companies like Amgen (AMGN) and Johnson & Johnson (JNJ) "could potentially achieve greater commercial synergies." However, the analyst thinks Celgene shareholders "may be satisfied with the current deal after quite a roller-coaster over the past 18 months."
MRK Merck
$76.26

2.22 (3.00%)

10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
11/06/18
PIPR
11/06/18
NO CHANGE
Target $3
PIPR
Overweight
OncoSec price target lowered to $3 from $5 at Piper Jaffray
After OncoSec (ONCS) reported preliminary Phase 2b KEYNOTE-695 data for Tavo combined with Merck's (MRK) Keytruda in PD-1 refractory melanoma patients, Piper Jaffray analyst Edward Tenthoff said the data, while early, show evidence of clinical activity, adding that he believes duration of response data will be important. However, OncoSec shares are down 52% today, which Tenthoff attributes to the lower response rate compared to prior data in different patients. The analyst keeps an Overweight rating on OncoSec shares, but lowered his price target on the stock to $3 from $5 as he pushed out his approval projections for Tavo by one year in the U.S. and Europe.
10/31/18
SBSH
10/31/18
NO CHANGE
Target $84
SBSH
Buy
Merck price target raised to $84 from $79 at Citi
Citi analyst Andrew Baum raised his price target for Merck to $84 and reiterates a Buy rating on the shares. The analyst says his 20%-plus above consensus non-GAAP earnings estimates beyond 2022 are driven by a continued view that the market underestimates Merck's market share in the PDx and PARP spaces with Keytruda and Lynparza respectively.
11/19/18
WELS
11/19/18
NO CHANGE
WELS
Pfizer price hikes may bring industry scrutiny, says Wells Fargo
Pfizer's (PFE) plans to raise prices on a host of medicines may put the drug industry "further in the crosshairs of an administration and Congress that is set on lowering drug prices," Wells Fargo analyst David Maris tells investors in a research note. The analyst points out that Pfizer earlier this year was criticized by the Trump administration for drug price increases, and as a result, it rolled the price increases back. However, Pfizer's new price increases "are not egregious" and its advance warning may be an attempt to see if minor price increases will also bring the administration's rebuke, says Maris. Nonetheless, given how public the administration's previous rebuke was, the analyst thinks Pfizer's confirmation Friday could "enflame the debate around drug pricing, especially since it comes less than two weeks following an election that resulted in Democrat control of the House with many having run on a drug-price-controls/Medicare-for-All platforms." Other large drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
NVS Novartis
$85.88

1.1 (1.30%)

12/18/18
COWN
12/18/18
NO CHANGE
COWN
Outperform
Cowen sees Sandoz deal as reinforcing Tilray's competitive positioning
Tilray's (TLRY) expanded global partnership with Novartis (NVS) division Sandoz can not only help expand its reach with pharmacists, physicians and distributors, it can also help Tilray capture early share in new medical cannabis markets as they come online, Cowen analyst Vivien Azer tells investors in a research note. Further, the analyst believes the partnership also helps legitimize cannabis in international markets, which could help influence countries considering medical cannabis legalization. Azer estimates international will represent 15% of Tilray's revenue in fiscal 2020 and 22% in fiscal 2021. Not only does the deal allow Tilray to expand geographic reach, but also to grow at scale, says Azer. And most notably, the Sandoz deal reinforces Tilray's competitive positioning, adds the analyst, who keeps an Outperform rating on the shares with a $150 price target. The stock in morning trading is up 9%, or $5.98, to $71.87.
12/11/18
JEFF
12/11/18
INITIATION
Target $105
JEFF
Buy
Novartis assumed with a Buy at Jefferies
Jefferies analyst Peter Welford assumed coverage of GNovartis with a Buy rating and $105 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum."
01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Underweight
Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company's pipeline and believes the shares are close to fair value.
PFE Pfizer
$42.99

0.95 (2.26%)

01/03/19
01/03/19
INITIATION

Pfizer initiates Phase 2b/3 clinical trial for PF-06651600
Pfizer announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body, and currently has no approved therapies. Based on the totality of the data and the emerging clinical profile, PF-06651600 was granted Breakthrough Therapy designation from FDA for the treatment of alopecia areata in September 2018. PF-06651600 will also continue to be evaluated for rheumatoid arthritis, Crohn's disease and ulcerative colitis.
12/28/18
BTIG
12/28/18
NO CHANGE
Target $190
BTIG
Buy
Sarepta's recent weakness represents 'buying opportunity', says BTIG
BTIG analyst Timothy Chiang kept his Buy rating and $190 price target on Sarepta (SRPT), noting that while the stock was among the best performing biotech names this year, its recent weakness represents a "potential buying opportunity". The analyst believes that the company's AAVrh74 micro-dystrophin gene therapy for the treatment of Duchenne Muscular Dystrophy program leads those of Pfizer (PFE) and Solid Biosciences (SLDB) and expects Sarepta to reach about $2B in peak U.S. sales by 2024.
RHHBY Roche
$0.00

(0.00%)

12/17/18
PIPR
12/17/18
NO CHANGE
PIPR
Proteostasis deal with Genentech strenghtens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Proteostasis (PTI), noting the company announced an agreement with Roche's (RHHBY) Genentech to license small molecule modulators of an undisclosed target that lie outside of Cystic Fibrosis, which makes the company eligible for $100M in upfront and milestone payments plus royalties. Tenthoff sees this deal strengthening Proteostasis' balance sheet. Additionally, Tenthoff is optimistic on Proteostasis' TripleRx combo, and expects full Phase I TripleRx data in Q1 of 2019. Longer term, the analyst anticipates TripleRx approval in 2021, with global sales of $2.0B by 2026.
12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
12/20/18
PIPR
12/20/18
NO CHANGE
Target $400
PIPR
Overweight
Survey shows 'solid fundamentals' for Biogen MS franchise, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Biogen (BIIB) with a $400 price target after surveying 100 neurologists. The survey feedback shows "solid fundamentals" for the company's multiple sclerosis portfolio, Raymond tells investors in a research note. He admits, however, that many investors are preoccupied with Tecfidera's intellectual property situation. Nonetheless, neurologists reported meaningful share gains for Tecfidera and Tysabri this quarter, says the analyst. Raymond believes worries over the impact to Biogen's multiple sclerosis franchise from Roche's (RHHBY) Ocrevus launch "may be behind us."
SNY Sanofi
$42.87

0.41 (0.97%)

12/11/18
12/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AT&T (T) upgraded to Buy from Neutral at Citi with analyst Michael Rollins saying he expects AT&T to further benefit from the "measured" promotional environment in wireless, while improving its competitive position from FirstNet and the marketing of its network enhancements, branded 5G Evolution. 2. Sanofi (SNY) upgraded to Buy from Hold at Jefferies with analyst Peter Welford saying he believes European large-cap pharmaceuticals are entering a period of sustained earnings momentum which should justify valuations above the historic average for the sector. 3. Total (TOT) upgraded to Buy from Neutral at BofA/Merrill. 4. Zynga (ZNGA) upgraded to Outperform from Neutral at Macquarie. 5. Allstate (ALL) upgraded to Hold from Sell at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
01/03/19
SBSH
01/03/19
NO CHANGE
Target $70
SBSH
Buy
Citi calls MyoKardia 'more interesting long term play' after Sanofi news
Citi analyst Mohit Bansal says that while some might see Sanofi (SNY) giving back all rights back to MyoKardia (MYOK) as a negative, he sees "significant strategic implications in longer term." The move gives MyoKardia more freedom to employ its "Divide and Conquer" precision strategy, Bansal tells investors in a research note titled "Full control makes MYOK an interesting long term play." The analyst also points out that Sanofi's decision was related to wanting U.S. control over Mavacamten, and is not related to the profile of the products. Bansal lowered his price target for MyoKardia to $70 from $90 and keeps a Buy rating on the shares.
01/03/19
MSCO
01/03/19
NO CHANGE
Target $70
MSCO
Overweight
MyoKardia shares oversold on Sanofi collaboration end, says Morgan Stanley
Morgan Stanley analyst Jeffrey Hung said MyoKardia (MYOK) management emphasized that Sanofi (SNY) wanted greater economics and maintained that efficacy and safety did not factor into Sanofi's decision to end their collaboration. His base case assumption is that MyoKardia will find another partner after more mature data are reported and he thinks the shares have been oversold following yesterday's announcement, Hung tells investors. He trimmed his price target on the stock to $70 from $72, but keeps an Overweight rating, stating that he believes the Phase 2 mavacamten data were promising and sees multiple catalysts over the next year.
AAPL Apple
$148.27

6.18 (4.35%)

01/04/19
NOMU
01/04/19
NO CHANGE
Target $300
NOMU
Buy
Nomura reiterates Broadcom as top semiconductor pick after 9% selloff
Broadcom (AVGO) has not underperformed the technology sector for two consecutive years, which speaks to management's focus of putting shareholder return first, Nomura Instinet analyst Romit Shah tells investors in a research not titled "Revisiting High Conviction View." After a volatile 2018, the analyst expects "strong share performance" going forward. The Broadcom profile will "slowly" shift from an Apple (AAPL) radio frequency supplier to diversified technology provider with a focus on capital return, says Shah. His $300 target price is predicated on multiple expansion from current levels "though below a five-year average multiple." The analyst adds that Broadcom remains his top pick in semiconductors for 2019 following yesterday's 9% selloff.
01/04/19
NOMU
01/04/19
DOWNGRADE
Target $70
NOMU
Neutral
Skyworks downgraded to Neutral from Buy at Nomura Instinet
Nomura Instinet analyst Krysten Sciacca downgraded Skyworks Solutions (SWKS) to Neutral and lowered her price target for the shares to $70 from $100. Following Apple's (AAPL) profit warning, the analyst believes growth headwinds from macro and trade uncertainty, as well as weak unit demand at the company's largest customers, will persist in 2019.
01/03/19
BTIG
01/03/19
UPGRADE
Target $94
BTIG
Buy
Green Dot upgraded to Buy from Neutral at BTIG
BTIG analyst Mark Palmer upgraded Green Dot (GDOT) to Buy from Neutral with a price target of $94, saying the recent 20% decline in its stock price from the early November highs has created an "attractive entry point for an evolving fintech story." The analyst notes that the company looks to have "sustainable momentum" after beating on consensus earnings and revenue for the past 12 quarters, also highlighting Green Dot's consistent progress in "repositioning its core prepaid debit card business". Palmer adds that he is positive on the company's "expanding roster of enterprise-level programs", and that its Banking as a Service partnerships now include Apple Pay Cash Card (AAPL), Intuit's (INTU) TurboTax prepaid card, Uber's Instant Pay and PayPal's (PYPL) cash in and cash out money services.
01/04/19
TIGR
01/04/19
NO CHANGE
TIGR
Strong Buy
Tigress reiterates Strong Buy on Apple following 'recent reset'
Tigress Financial analyst Ivan Feinseth reiterated a Strong Buy rating on Apple following the company's "recent reset in forward-looking expectations" and the subsequent pullback in the stock. Feinseth believes the ongoing monetization of its ecosystem will drive future revenue growth, and that Apple can further grow its services base revenue by offering all-inclusive services on a subscription basis. The analyst also was positive on the company focusing its efforts on expanding its music streaming service, growing its smart wearables presence with the Apple Watch, and developing new AI technologies and AR/VR capabilities for use in existing and future products. Apple is in Tigress Financial's Research Focus List and its Focus Opportunity Portfolio.
SSNLF Samsung
$0.00

(0.00%)

11/26/18
RBCM
11/26/18
NO CHANGE
Target $29
RBCM
Outperform
HP executing well, positioned to report in-line Q4, says RBC Capital
RBC Capital analyst Amit Daryanani kept his Outperform rating and $29 price target on HP Inc (HPQ) ahead of its earnings this week, saying the company is positioned to report inline result for Q4 as it continues to execute well. The analyst notes that the stock offers a 10% free cash flow yield and could see some multiple expansion from better organic earnings growth, even though the company is contending with FX related headwinds, lower memory pricing trends, and the declining pace of install base at Samsung (SSNLF) in printing.
11/02/18
NEED
11/02/18
NO CHANGE
Target $125
NEED
Buy
Universal Display price target lowered to $125 from $145 at Needham
Needham analyst James Ricchiuti lowered his price target on Universal Display (OLED) to $125 after its Q3 results and implied guidance suggesting a sequential revenue decline in Q4 of up to 9%. The analyst cites the management's discussion of weaker recovery in materials revenue amid weakness in the smartphone market and the complications from ASC606 standard magnifying changes in the impact of license revenue by a customer such as Samsung (SSNLF). Ricchiuti keeps his Buy rating on Universal Display, saying that the expected decline in the stock price today will bring its risk-reward to "particularly attractive" levels based on the company's 2019 growth expectations.
12/10/18
BNCH
12/10/18
NO CHANGE
Target $35
BNCH
Buy
Xperi settlement removes Samsung uncertainty, says Benchmark
After Xperi (XPER) announced a patent license agreement with Samsung (SSNLF) that it said settles all outstanding legal matters between the parties, Benchmark analyst Gary Mobley said he believes the pact "removes nearly all of the uncertainty that has plagued the shares during the past two years." He raised his price target on Xperi shares to $35 from $25 to account for his higher FY19 estimates and keeps an Buy rating on the stock, which he still views as undervalued.
12/11/18
CHLM
12/11/18
NO CHANGE
Target $28
CHLM
Buy
Xperi price target raised to $28 from $20 at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for Xperi to $28 from $20 (XPER), while reiterating a Buy rating on the shares. The analyst notes that the the company's Samsung (SSNLF) settlement is a critical event in its history as it shows that its portfolio has substantial ongoing value, and that Xperi is willing to be patient to find a fair settlement.
T AT&T
$30.33

0.77 (2.60%)

12/11/18
MSCO
12/11/18
NO CHANGE
Target $37
MSCO
Overweight
AT&T likely to raise dividend despite deleveraging goals, says Morgan Stanley
Morgan Stanley analyst Simon Flannery said he expects AT&T to raise its quarterly dividend by 1c to 51c from 50c per share as early as this Friday, which would be in-line with its timing last year. He would view such an increase, which would not be that notable normally but takes on added significance due to the company's high leverage and desire to delever, as a signal of confidence in the recent 2019 business and financial outlook, Flannery tells investors. He maintains an Overweight rating and $37 price target on AT&T shares.
01/02/19
BOFA
01/02/19
NO CHANGE
BOFA
Top 10 US Ideas for Q1 2019 at BofA/Merrill
BofA/Merrill's Alpha Generation Research team introduced its latest Top 10 US Ideas for Q1 2019. The list consists of 9 Buys that are Cigna (CI), Disney (DIS), Equinix (EQIX), Honeywell (HON), Lockheed Martin (LMT), Marvell (MRVL), Procter & Gamble (PG), AT&T (T), and Tapestry (TPR) and 1 Underperform rating which is Campbell Soup (CPB).
12/11/18
SBSH
12/11/18
UPGRADE
Target $34
SBSH
Buy
Citi upgrades AT&T to Buy with shares down 23% year-to-date
Citi analyst Michael Rollins upgraded AT&T to Buy from Neutral with an unchanged price target of $34. The stock closed yesterday down 24c to $29.91. The analyst expects AT&T to further benefit from the "measured" promotional environment in wireless, while improving its competitive position from FirstNet and the marketing of its network enhancements, branded 5G Evolution. Further, the company has "several levers" to manage free cash flow and support its net debt deleveraging goals for 2019, Rollins tells investors in a research note. In addition, the analyst believes the stock's 23% decline year-to-date provides a better risk/reward scenario. AT&T trades at a price-to-earnings ratio of about eight times the analyst's revised 2019 outlook and at a dividend yield of about 6.7%. He sees a buying opportunity at current share levels.
AL Air Lease
$31.96

2.29 (7.72%)

03/14/18
MACQ
03/14/18
INITIATION
Target $53
MACQ
Outperform
Air Lease initiated with an Outperform on solid growth at Macquarie
Macquarie analyst Susan Donofrio initiated Air Lease with an Outperform and $53 price target. Donofrio said the company is positioned for stable earnings and strong profitability driven by a young fleet, solid growth profile and experienced management team.
07/31/18
07/31/18
DOWNGRADE
Target $64

Equal Weight
AerCap downgraded to Equal Weight after outperformance at Stephens
As previously reported, Stephens analyst Vincent Caintic downgraded AerCap (AER) to Equal Weight from Overweight, noting that the stock has outperformed both Air Lease (AL) and Aircastle (AYR) year-to-date. Caintic is finding it more difficult for AerCap to show core EPS growth without "lofty assumptions" and prefers Aer Lease, which he thinks can continue with double-digit EPS growth year-over-year. He maintains a $64 price target on AerCap shares.
10/10/18
GHSC
10/10/18
INITIATION
Target $60
GHSC
Buy
Air Lease initiated with a Buy at Seaport Global
Seaport Global analyst Josh Sullivan initiated Air Lease with a Buy and $60 price target. Sullivan said the global air traffic demand multiplier is gaining strength, providing strong dynamics, and Air Lease's strategy of aggressively building order slots for next-gen aircraft positions the company to double its aircraft fleet just at the right moment given supply/demand dynamics.
03/13/18
MACQ
03/13/18
INITIATION
Target $53
MACQ
Outperform
Air Lease initiated with an Outperform at Macquarie
Macquarie initiated Air Lease with an Outperform and $53 price target.
DXC DXC Technology
$57.33

2.69 (4.92%)

11/26/18
COWN
11/26/18
UPGRADE
COWN
Outperform
DXC Technology upgraded to Outperform from Market Perform at Cowen
11/26/18
COWN
11/26/18
UPGRADE
Target $80
COWN
Outperform
DXC Technology upgraded to Outperform at Cowen
As reported previously, Cowen analyst Bryan Bergin upgraded DXC Technology to Outperform from Market Perform as he sees significant upside potential for patient investors. He said the company can employ significant financial flexibility to execute toward revenue stabilization. The analyst sees management as a proven team of operators with a coherent plan, and believes the stock's depressed valuation supports a favorable risk/reward. However, Bergin lowered his price target to $80 from $90 on DXC Technology shares.
11/13/18
RHCO
11/13/18
NO CHANGE
Target $75
RHCO
Buy
DXC Technology price target lowered to $75 from $102 at SunTrust
SunTrust analyst Frank Atkins lowered his price target on DXC Technology to $75 following its investor day last week after the company provided a medium-term annualized revenue growth outlook of 2%-4% by 2022. The analyst lowers his FY19 revenue view to $20.9B from $21.7B and FY20 to $20.9B from $21.8B but expects DXC Technology to generate a steady margin improvement. Atkins adds that he view the company's recently announced stock buyback as a good use of capital.
11/13/18
JPMS
11/13/18
NO CHANGE
Target $83
JPMS
Overweight
DXC Technology price target lowered to $83 from $92 at JPMorgan
JPMorgan analyst Tien-tsin Huang lowered his price target for DXC Technology to $83 following last week's investor day. While the company guided to "slight" revenue growth, the stock is "too cheap" at current levels, Huang tells investors in a research note. The analyst believes capital deployment is a "key catalyst to watch" and he expects DXC to be active on the buyback front. He maintains an Overweight rating on shares of DXC Technology.
MS Morgan Stanley
$41.30

1.62 (4.08%)

01/04/19
OPCO
01/04/19
NO CHANGE
OPCO
Outperform
Oppenheimer sees 'poor' quarter for banks' capital markets businesses
Oppenheimer analyst Chris Kotowski previewed the Q4 outlook for financial institutions, telling investors in a research note that the significant market volatility in December suggests a poor quarter for the banks' capital markets businesses which are likely to persist into 1H19, adding that the weaker equity markets will likely limit ECM revenues. Kotowski says he believes the less banks pay for their shares in the current market turmoil, the more the stocks are worth in the long run. He continue to recommend Bank of America (BAC), Citi (C), CIT Group (CIT), Goldman Sachs (GS), Morgan Stanley (MS) and US Bancorp (USB).
12/12/18
12/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. eBay (EBAY) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Brian Nowak saying he had been wrong in his prior view about how quickly core marketplaces would deteriorate. 2. Bank of America (BAC) and Morgan Stanley (MS) were downgraded to Market Perform from Outperform at Keefe Bruyette. 3. Mosaic (MOS) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas saying there are signs of increased phosphate exports from China, which have the potential to loosen the supply/demand balance in phosphate in 2019, leading to a weaker phosphate price dynamic. 4. Verizon (VZ) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Simon Flannery saying he contends that the stock's 11% year-to-date advance prices in the company's good news, including its $4B free cash flow improvement this year. 5. Fluor (FLR) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jerry Revich saying Fluor management noted that it was underbid on a major U.S. liquefied natural gas project that the analyst expected to be a catalyst in 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/18
KBWI
12/12/18
NO CHANGE
KBWI
Keefe downgrades Universal Banks sector to Market Weight from Overweight
Keefe Bruyette analyst Frederick Cannon downgraded his rating on the Universal Banks sector to Market Weight from Overweight. Universal Bank stocks underperformed the broader market this year as loan growth repeatedly disappointed and macroeconomic risks weighed on shares into year-end, Cannon tells investors in a research note. As the analyst looks into 2019, he "does not see enough positive catalysts emerging" that could move the group higher. Cannon says Universal Banks are currently trading at 60% of the S&P 500 based on 2019 consensus earnings estimates, but that relative valuation is not enough to make him stay constructive on the group. His firm last night also downgraded shares of Bank of America (BAC) and Morgan Stanley (MS) to Market Perform from Outperform.
12/11/18
KBWI
12/11/18
DOWNGRADE
Target $45
KBWI
Market Perform
Morgan Stanley downgraded to Market Perform with $45 target at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl downgraded Morgan Stanley to Market Perform from Outperform and lowered his price target for the shares to $45 from $56. The analyst sees a lack of catalysts in 2019.
MYL Mylan
$28.85

1.61 (5.91%)

11/15/18
11/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Buy from Hold at Argus with analyst Jasper Hellweg saying the stock appears to be close to an inflection after several quarters of underperformance. 2. CopyTele (COPY) upgraded to Outperform from Market Perform at BMO Capital. 3. Voyager Therapeutics (VYGR) upgraded to Strong Buy from Outperform at Raymond James. 4. Athenex (ATNX) upgraded to Overweight from Neutral at JPMorgan with analyst Leon Chik saying more clinical data and progress in new drug trials should boost investor sentiment in 2019. 5. Coty (COTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Shannon Coyne saying that her downgrade in August was driven by concerns around the company's supply chain issues, but believes that these factors have now been fully priced in after the management withdrew its guidance and consensus earnings have been pulled back by about 30%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/18
PIPR
12/18/18
NO CHANGE
Target $400
PIPR
Overweight
Piper says Biogen weakness on Tecfidera patent concerns a buying opportunity
Piper Jaffray analyst Christopher Raymond attributes today's weakness in Biogen (BIIB) shares to a competitor's research note that raised concerns about Mylan's (MYL) IPR challenge of Tecfidera's '514 dosing patent. While acknowledging that a worst case scenario does remove about $50 per share from his sum-of-the-parts valuation for Biogen, Raymond said his read of the current case, along with the fact that the '514 patent previously survived Forward Pharma's 2014 interference claim and Hayman Capital's IPR in 2015, lead him to view such scenario as "very low probability." The analyst, who views the weakness as a buying opportunity, keeps an Overweight rating and $400 price target on Biogen shares, which are down 7% to $291.31 in afternoon trading.
11/29/18
MAXM
11/29/18
INITIATION
Target $3
MAXM
Buy
Agile Therapeutics initiated with a Buy at Maxim
Maxim analyst Caroline Palomeque initiated Agile Therapeutics (AGRX) with a Buy rating and a price target of $3, saying that she likes the risk-reward on the stock as the company approaches an NDA resubmission for its Twirla - a low-dose combined hormone contraceptive transdermal patch. The analyst cites the large potential market opportunity for the product, with combined hormone contraceptive market generating about $4B and the current patch availability being limited to Mylan's (MYL) Xulane. Palomeque further contends that Twirla "offers a low-dose, safer estradiol, potentially with no 'black box' warning."
NAV Navistar
$27.15

0.955 (3.65%)

12/24/18
BMOC
12/24/18
NO CHANGE
Target $35
BMOC
Market Perform
Navistar may struggle with multiple expansion on peaking cycle, says BMO Capital
BMO Capital analyst Joel Tiss lowered his price target on Navistar to $35 from $40 and kept his Market Perform rating, saying that while the company is achieving higher profitability through improvement in product line-up, investors should be patient. The analyst notes that a "significant multiple expansion" for the stock would be difficult amid a peaking North American Class 8 cycle, warning that the timing, duration, and depth of the downturn are difficult to forecast. Tiss is also raising his FY19 EPS view to $3.55 from $3.25 but lowers his FY20 view to $2.75 from $3.40.
12/20/18
LOOP
12/20/18
NO CHANGE
Target $44
LOOP
Buy
Loop Capital affirms Buy rating on Navistar after 'strong' Q4 results
Navistar continues to report better than expected growth, driven by a strong Class 8 market and share gains due to new product launches, Loop Capital analyst Jeffrey Kauffman tells investors in a research note. The analyst reaffirms a Buy rating on the shares with a $44 price target. Investors have given management credit for Navistar's financial turnaround, but not for the upside that exists as a result of market share gains and potential strategic opportunities, says Kauffman. He views the company's Q4 results this week as "strong."
12/19/18
RBCM
12/19/18
NO CHANGE
Target $32
RBCM
Sector Perform
Navistar price target lowered to $32 from $45 at RBC Capital
RBC Capital analyst Seth Weber lowered his price target on Navistar to $32 and kept his Sector Perform rating, saying that while the company is executing well with market share gains in the currently "healthy" environment, he is concerned with the "truck cycle duration" relative to its investment sentiment and valuation. The analyst lowers his FY19 EBITDA view to $885M from $905M to account for his mixed outlook and also states that his neutral stance reflects his "caution on relatively modest implied incremental margins and cycle peak debate".
12/19/18
BARD
12/19/18
NO CHANGE
Target $54
BARD
Outperform
Navistar upside opportunity just beginning, says Baird
Baird analyst David Leiker said the Navistar turnaround is officially in the rearview mirror and yesterday's move is "just the beginning" of what he sees as an opportunity for upside. The analyst sees market share gains, improving margins, and improvement in the balance sheet as all contributing to upside. Leiker reiterated his Outperform rating and raised his price target to $54 from $53 on Navistar shares.

TODAY'S FREE FLY STORIES

13:15
01/21/19
01/21
13:15
01/21/19
13:15
General news
IMF trimmed global growth amid "no-deal" Brexit and trade war concerns »

IMF trimmed global growth…

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$37.50

0.6 (1.63%)

, BA

Boeing

$364.79

5.52 (1.54%)

09:36
01/21/19
01/21
09:36
01/21/19
09:36
Hot Stocks
Air Lease announces lease placement of Boeing 737 MAX 9 »

Air Lease (AL) announced…

AL

Air Lease

$37.50

0.6 (1.63%)

BA

Boeing

$364.79

5.52 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 21

    Feb

  • 28

    May

UTSI

UTStarcom

$3.22

0.1 (3.21%)

09:34
01/21/19
01/21
09:34
01/21/19
09:34
Hot Stocks
UTStarcom says TDI paid $4.54 per share to increase stake to 9.9% »

UTStarcom announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$194.63

4.19 (2.20%)

09:31
01/21/19
01/21
09:31
01/21/19
09:31
Hot Stocks
Vertex says European Commission granted label extension for Orkambi »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

ALNY

Alnylam

$83.08

2.4 (2.97%)

09:30
01/21/19
01/21
09:30
01/21/19
09:30
Hot Stocks
Alnylam, Israel's Medison partner to commercialize Onpattro, RNAi portfolio »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THO

Thor Industries

$66.56

1.905 (2.95%)

09:26
01/21/19
01/21
09:26
01/21/19
09:26
Hot Stocks
Thor finalizing talks to exclude EHG's North American operations from deal »

Thor Industries provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLWTY

Panalpina

$0.00

(0.00%)

08:44
01/21/19
01/21
08:44
01/21/19
08:44
Downgrade
Panalpina rating change at Jefferies »

Panalpina downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFGSY

Eiffage

$0.00

(0.00%)

08:41
01/21/19
01/21
08:41
01/21/19
08:41
Upgrade
Eiffage rating change at Barclays »

Eiffage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVFCF

Television Francaise 1

$0.00

(0.00%)

08:40
01/21/19
01/21
08:40
01/21/19
08:40
Downgrade
Television Francaise 1 rating change at Citi »

Television Francaise 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVDY

Atresmedia

$0.00

(0.00%)

08:37
01/21/19
01/21
08:37
01/21/19
08:37
Upgrade
Atresmedia rating change at Citi »

Atresmedia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDPAY

Tod's

$0.00

(0.00%)

08:36
01/21/19
01/21
08:36
01/21/19
08:36
Downgrade
Tod's rating change at Citi »

Tod's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.